Sotera Health Company (SHC - Free Report) reported $310.24 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 23.3%. EPS of $0.26 for the same period compares to $0.25 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $300.54 million, representing a surprise of +3.23%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.26.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Sotera Health Company performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Revenues- Sterigenics: $172.20 million versus the two-analyst average estimate of $168.51 million. The reported number represents a year-over-year change of +6.5%.
- Net Revenues- Nelson Labs: $58.21 million compared to the $55.28 million average estimate based on two analysts. The reported number represents a change of +4.3% year over year.
- Net Revenues- Nordion: $79.84 million versus the two-analyst average estimate of $78.75 million. The reported number represents a year-over-year change of +134.2%.
- Segment Income- Sterigenics: $94.75 million versus $92.95 million estimated by two analysts on average.
- Segment Income- Nelson Labs: $18.68 million versus $17.15 million estimated by two analysts on average.
- Segment Income- Nordion: $53.32 million versus $51.97 million estimated by two analysts on average.
View all Key Company Metrics for Sotera Health Company here>>>Shares of Sotera Health Company have returned +13.6% over the past month versus the Zacks S&P 500 composite's +3.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
Sotera Health Company (SHC - Free Report) reported $310.24 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 23.3%. EPS of $0.26 for the same period compares to $0.25 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $300.54 million, representing a surprise of +3.23%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.26.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Sotera Health Company performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Revenues- Sterigenics: $172.20 million versus the two-analyst average estimate of $168.51 million. The reported number represents a year-over-year change of +6.5%.
- Net Revenues- Nelson Labs: $58.21 million compared to the $55.28 million average estimate based on two analysts. The reported number represents a change of +4.3% year over year.
- Net Revenues- Nordion: $79.84 million versus the two-analyst average estimate of $78.75 million. The reported number represents a year-over-year change of +134.2%.
- Segment Income- Sterigenics: $94.75 million versus $92.95 million estimated by two analysts on average.
- Segment Income- Nelson Labs: $18.68 million versus $17.15 million estimated by two analysts on average.
- Segment Income- Nordion: $53.32 million versus $51.97 million estimated by two analysts on average.
View all Key Company Metrics for Sotera Health Company here>>>Shares of Sotera Health Company have returned +13.6% over the past month versus the Zacks S&P 500 composite's +3.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
Get the latest research report on SHC - FREE